INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

Authors
Category Primary study
JournalHemaSphere
Year 2023
This article has no abstract
Epistemonikos ID: 4bdd6108afab44bab1f602a9673c53a4af81a1bf
First added on: Apr 25, 2026